Peptide Portal: Legal Compliance Guide

Disclaimer: This document is for informational purposes only and does not constitute legal advice. Consult with a licensed attorney specializing in FDA/FTC law before making business decisions.

Last Updated: May 2026 Jurisdiction Focus: California, United States (Federal)

Table of Contents

1. Executive Summary
2. The "Research Use Only" Problem
3. Business Model Analysis
   • Current: Directory/Affiliate Model
   • Future: Order Facilitation Model
   • Eventual: Own Peptide Brand
4. Federal Regulatory Framework
   • FDA Regulations
   • FTC Requirements
   • DEA Considerations
5. California State Requirements
6. Content & Marketing Compliance
7. Risk Assessment by Business Model
8. Compliance Recommendations
9. Sources

Executive Summary

The Core Problem

Your concern is valid and legally significant. The FDA has made clear that "Research Use Only" disclaimers do not protect websites that market peptides for human consumption. The agency looks at the totality of circumstances—including:

• Product descriptions mentioning human effects
• Dosing guides or administration instructions
• Testimonials about personal use
• Weight loss, anti-aging, or performance language
• Selling peptides with syringes or bacteriostatic water
• Shipping to residential addresses
• Marketing language suggesting therapeutic benefits

Key Quote from FDA: "A disclaimer is not a shield when everything around it describes a therapeutic use."

Risk Summary by Business Model

The "Research Use Only" Problem

The Disclaimer Era Is Over

As of 2025-2026, the FDA has dramatically increased enforcement against the "research use only" loophole:

• 14 warning letters issued in 2024
• 41+ warning letters in early 2026 alone
• Criminal prosecutions initiated against company principals
• Import Alert 66-78 expanded to block more peptides at the border

What Triggers FDA Enforcement

The FDA determines "intended use" from any relevant source, not just explicit label claims:

1. Marketing language - "fat loss," "anti-aging," "muscle growth," "appetite suppression"
2. Product descriptions - describing mechanisms in humans (even without claims)
3. Bundled products - selling with syringes, bacteriostatic water, or mixing supplies
4. Dosing information - any guidance on how to administer
5. Testimonials - user reviews describing personal effects
6. Target audience - shipping to residential addresses, accepting individual orders
7. Website context - tools like "stack builders," dosage calculators, before/after imagery

Case Study: December 2024 Warning Letters

The FDA issued warning letters to Prime Peptides, Summit Research, SwissChems, and others for selling semaglutide, tirzepatide, and retatrutide. Despite "research only" disclaimers, the FDA found:

"The products are offered or used for a purpose for which [they are] neither labeled nor advertised... Evidence of intended use may include... the circumstance that a manufacturer knew that its product was being offered or used for [human consumption]."

Business Model Analysis

Current: Directory/Affiliate Model

What you're doing: Providing information about peptides and linking to vendor websites.

Legal Framework

Section 230 Protection (Limited)

• Section 230 of the Communications Act provides some immunity for "interactive computer services" hosting third-party content
• However, this protection has significant limitations:
  • Does not protect against federal criminal law violations
  • Does not apply if you "contribute materially to the alleged illegality"
  • Does not protect against FTC enforcement for your own promotional content

FTC Liability

• The FTC has issued joint warning letters with the FDA to affiliate marketers
• Affiliates can be held liable for:
  • Promoting unapproved drugs (even through links)
  • Making unsubstantiated health claims
  • Failing to disclose material connections (commissions)
  • False or misleading advertising

Key FTC Precedent: "Warning letters issued by FDA and FTC have targeted not the company making the product... but were sent to the middleman marketer, who likely does not produce or possess the product, but who is promoting and profiting from its sale."

Risk Factors for Your Site

HIGH RISK ELEMENTS (if present):

• Dosing calculators or administration guides
• Stack builders suggesting combinations for effects
• Content describing human benefits (even in "research" framing)
• User testimonials about personal use
• Affiliate links without clear disclosure
• Language like "best peptides for fat loss" or "anti-aging peptides"

LOWER RISK ELEMENTS:

• Purely chemical/scientific information
• Academic citations only
• No commercial relationship with vendors
• Clear, prominent "not for human use" language
• No dosing, administration, or use guidance

Affiliate Disclosure Requirements

Under FTC guidelines (16 CFR Part 255), you must:

1. Disclose material connections clearly and conspicuously
2. Place disclosures near the affiliate links (not buried in footer)
3. Use obvious language: "I earn a commission if you purchase through these links"
4. Ensure disclosures are:
   • Visible (not hidden or in tiny font)
   • Understandable by ordinary consumers
   • Present on every page with affiliate content

Penalty: Up to $51,744 per violation for FTC disclosure failures.

Future: Order Facilitation Model

What you'd be doing: Taking orders from customers and placing them with vendors on their behalf.

Legal Classification

This model would likely classify you as a distributor under FDA regulations, subjecting you to:

1. FDA Facility Registration - Required for establishments that distribute drug products
2. Drug Listing Requirements - Must list all products with FDA
3. Adverse Event Reporting - Obligations to report safety issues
4. Record-Keeping Requirements - Chain of custody documentation

Critical Legal Issues

1. Introduction into Interstate Commerce

"Causing the introduction or delivery for introduction of [unapproved drugs] into interstate commerce is prohibited." — FDA Warning Letter standard language

By facilitating orders, you become part of the distribution chain for products the FDA considers unapproved new drugs (not research chemicals).

2. Aiding and Abetting

You could face liability for:

• Facilitating the sale of unapproved drugs
• Circumventing the prescription requirement
• Operating as an unlicensed drug distributor

3. State Licensing Requirements

Most states require licenses for drug wholesale distribution:

• California Board of Pharmacy licensing
• Compliance with 21 CFR Part 111 (GMP standards)
• Potential need for Wholesale Drug Distributor license

4. Payment Processing Issues

Major payment processors (Visa, Mastercard, PayPal) have policies against:

• Unapproved pharmaceuticals
• Products marketed for human consumption without approval
• High-risk supplement categories

Risk Assessment: HIGH to VERY HIGH

This model essentially makes you a drug distributor in the eyes of regulators. The "facilitator" framing does not provide meaningful legal protection.

Eventual: Own Peptide Brand

What you'd be doing: Manufacturing or private-labeling peptides for sale.

Legal Classification Options

Option A: Dietary Supplement (Not Viable for Peptides)

Peptides cannot be sold as dietary supplements because:

• They are not "dietary ingredients" under DSHEA
• Many were studied as drugs before being marketed as supplements (exclusion clause)
• FDA has explicitly stated peptides cannot be supplements

Option B: "Research Use Only" Manufacturer

Requirements:

• FDA registration as API manufacturer
• Certificate of Analysis for each batch
• Cannot market to consumers
• Cannot ship to residential addresses
• Must require institutional documentation
• Cannot include any language suggesting human use

This model has become increasingly difficult:

"Suppliers who ship peptides to residential addresses, accept orders from individuals without institutional affiliation, or market compounds with language suggesting therapeutic benefit are operating outside federal compliance." — FDA Guidance, March 2025

Option C: FDA-Approved Drug (Proper Path)

• New Drug Application (NDA) or Biologics License Application (BLA)
• Clinical trials demonstrating safety and efficacy
• Years of development, tens of millions in costs
• Only viable for major pharmaceutical companies

Option D: Compounding Pharmacy Partnership

You could work with a licensed 503A or 503B pharmacy to compound peptides:

• Requires valid prescription
• Limited to peptides on the FDA bulks list
• Must partner with licensed compounding pharmacy
• Patient must have physician relationship

Currently approved for compounding: NAD+, sermorelin, and limited others Pending FDA review (July 2026): BPC-157, KPV, TB-500, MOTs-C, Semax, Epitalon

Required Registrations & Licenses (California)

1. FDA Drug Establishment Registration - 21 CFR 207
2. National Drug Code (NDC) - For each product
3. California Board of Pharmacy License - If compounding
4. California Wholesale Drug Distributor License - Business & Professions Code §4160
5. General Business License - LLC or Corporation
6. Reseller's Permit - For wholesale purchases
7. Seller's Permit - For collecting sales tax

Risk Assessment: VERY HIGH without FDA approval pathway

Federal Regulatory Framework

FDA Regulations

Drug Definition (21 USC §321(g)(1))

A product becomes a "drug" when it is intended for:

• Diagnosis, cure, mitigation, treatment, or prevention of disease
• Affecting the structure or function of the body

Intent is determined by:

• Labeling and advertising claims
• Marketing context
• Website content
• Product design and bundling
• Manufacturer's knowledge of use

Key Regulatory Citations

Enforcement Tools

1. Warning Letters - First step, requires corrective action
2. Import Alerts - Block products at border
3. Seizure - Physical confiscation of products
4. Injunctions - Court orders to cease activity
5. Criminal Prosecution - For knowing violations (felony)

FTC Requirements

Health Product Advertising (FTC Act §5)

All health-related claims must be:

• Truthful - Not false or misleading
• Substantiated - Backed by competent scientific evidence
• Disclosed - Material connections revealed

Endorsement Guidelines (16 CFR Part 255)

For testimonials:

• Must reflect typical results (or disclose typical results)
• "Results not typical" disclaimers do not cure deception
• Must have scientific substantiation for underlying claims
• Expert endorsers must have appropriate qualifications

Penalties

• Up to $51,744 per violation (civil penalties)
• Disgorgement of profits
• Corrective advertising requirements
• Permanent injunctions

DEA Considerations

Most peptides are not DEA-scheduled controlled substances. However:

• Human Growth Hormone (somatropin) - Special federal restrictions (21 USC §333(e))
• Certain secretagogues - Under review for potential scheduling
• Anabolic steroids - Schedule III (peptides are structurally different)

California State Requirements

Business and Professions Code

Section 17200 (Unfair Competition)

• Prohibits "unlawful, unfair, or fraudulent business acts"
• Private right of action (consumers can sue)
• Covers false advertising and deceptive practices

Section 17500 (False Advertising)

• Prohibits false or misleading advertising
• Criminal penalties possible

Consumer Legal Remedies Act (CLRA)

• Provides private right of action for consumers
• Covers deceptive representations in consumer transactions
• Class action liability exposure

California Board of Pharmacy

• Follows FDA guidance on compounding
• Has issued 30+ enforcement actions against peptide compounders since 2023
• Maintains state-level restricted substance list
• Licenses wholesale drug distributors

California Nutrition Law (B&P Code §2585-2586.8)

• Allows providing nutritional advice about supplements
• Does NOT allow stating products cure disease without licensure
• Requires clear disclaimers on limitations

Content & Marketing Compliance

What You CANNOT Say (Examples)

What You MAY Be Able to Say (With Caution)

Critical Caveat: Even "acceptable" content becomes problematic if:

• Combined with dosing calculators
• Surrounded by human use context
• Used alongside testimonials
• Part of a "stack builder" suggesting combinations

The Stack Builder Problem

Your stack builder tool specifically raises concerns because:

1. Suggests combinations - Implies knowledge of human effects
2. Implies use case - "Building a stack" is user-oriented language
3. Educational framing - Describes what each peptide does
4. Practical application - Goes beyond pure research information

Recommendation: Review this tool with legal counsel before continuing to use it.

Risk Assessment by Business Model

Current Model: Directory/Affiliate

Order Facilitation Model

Own Brand Model

Compliance Recommendations

Immediate Actions (Current Model)

1. Legal Review

   • Engage FDA/FTC specialized attorney
   • Conduct comprehensive content audit
   • Review all marketing materials
   • Assess stack builder and similar tools

2. Disclosure Compliance

   • Add clear affiliate disclosures near all affiliate links
   • Format: "We earn a commission if you purchase through these links"
   • Include on every page with commercial relationships
   • Make disclosures visible and prominent

3. Content Audit

   • Remove or modify dosing guides
   • Remove human-use testimonials
   • Eliminate therapeutic claims
   • Review stack builder for implied use cases
   • Add prominent research-only disclaimers

4. Disclaimer Enhancement

   • "For laboratory research use only"
   • "Not for human or veterinary use"
   • "Not intended to diagnose, treat, cure, or prevent any disease"
   • "Consult a licensed healthcare provider for medical advice"

5. Vendor Due Diligence

   • Document vendor compliance status
   • Avoid linking to vendors with FDA warning letters
   • Consider removing vendors selling GLP-1 peptides (high enforcement priority)

For Order Facilitation Model

Recommendation: Do not proceed without comprehensive legal analysis.

If you do proceed:

1. Obtain California Wholesale Drug Distributor license
2. FDA facility registration
3. Implement prescription verification (if applicable)
4. Establish compliance monitoring program
5. Obtain adequate liability insurance
6. Prepare for payment processing challenges

For Own Brand Model

Recommendation: Extremely high risk without FDA approval pathway.

If pursuing:

1. Consult specialized pharmaceutical regulatory counsel
2. Explore 503B outsourcing facility partnership
3. Consider focusing only on peptides on FDA bulks list
4. Budget for full regulatory compliance program
5. Expect significant barriers to market entry

Alternative Business Models to Consider

Lower-Risk Alternatives

1. Educational Content Only

   • No affiliate relationships
   • No commercial component
   • Pure scientific information
   • Academic citation focus
   • Removes FTC/commercial liability

2. Physician Referral Network

   • Partner with licensed telemedicine providers
   • Refer users to legitimate medical channels
   • Stay out of product distribution entirely
   • Monetize through referral fees to medical providers

3. Compounding Pharmacy Partnerships

   • Work only with licensed 503A/503B pharmacies
   • Require prescriptions
   • Focus on FDA-approved compounding list
   • Legitimate medical supervision model

4. Laboratory Supply Focus

   • Target only verified research institutions
   • Require institutional documentation
   • No residential shipping
   • Full RUO compliance program

Sources

FDA Sources

• FDA Warning Letters Database
• Summit Research Peptides Warning Letter (12/10/2024)
• FDA Registration and Listing
• FDA General/Specific Intended Use Guidance
• Federal Register: Regulations Regarding "Intended Uses"

FTC Sources

• FTC Health Products Compliance Guidance
• FTC Endorsements, Influencers, and Reviews
• 16 CFR Part 255 - Endorsement Guides

Legal Analysis Sources

• Regulatory Status of Peptide Compounding in 2025 - Frier Levitt
• Are Peptides Legal in the U.S.? - Florida Healthcare Law Firm
• The Unregulated World of Peptides - Holt Law
• Do You Need A License To Sell Peptides - LumaLex Law
• California Peptide Laws - PeptideLaws.com

Enforcement Tracking

• The 'Research Use Only' Loophole Just Closed - Policy Canary
• FDA Targets GLP-1 and Peptide Compounding - Health Law Alliance

State Resources

• California Business and Professions Code
• California Board of Pharmacy

Document History

Next Steps:

1. Share this document with legal counsel for review
2. Conduct internal content audit using the checklists above
3. Make compliance decisions based on risk tolerance
4. Document all compliance efforts for potential regulatory defense